Anupam Rama
Stock Analyst at JP Morgan
(4.30)
# 406
Out of 5,090 analysts
292
Total ratings
48.13%
Success rate
18.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Maintains: Underweight | $7 → $6 | $6.91 | -13.17% | 1 | Nov 18, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $17 → $20 | $11.00 | +81.82% | 7 | Nov 18, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $29 → $32 | $27.21 | +17.60% | 6 | Nov 18, 2025 | |
| ENTA Enanta Pharmaceuticals | Initiates: Overweight | $17 | $14.60 | +16.44% | 1 | Nov 14, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $40 → $33 | $20.32 | +62.40% | 11 | Nov 12, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $55 → $57 | $34.40 | +65.72% | 10 | Nov 12, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $53 → $52 | $44.90 | +15.81% | 11 | Nov 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $26 → $27 | $7.92 | +240.91% | 5 | Nov 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $76 → $77 | $73.64 | +4.56% | 12 | Nov 7, 2025 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $18 → $19 | $9.90 | +91.92% | 14 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $11 | $5.77 | +90.64% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $36 | $23.63 | +52.35% | 18 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $171 → $179 | $155.51 | +15.11% | 19 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $24.34 | -1.40% | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $35.87 | +120.24% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $44 | $38.77 | +13.49% | 8 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 | $10.61 | +3.68% | 12 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $220.36 | -9.24% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $37 | $41.71 | -11.29% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.25 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $22.26 | +7.82% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $44.41 | +80.14% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $36.38 | +221.61% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $19.50 | +161.54% | 12 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $35.00 | +25.71% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $41.67 | -4.01% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $109.60 | +14.05% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.34 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.66 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.95 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.61 | +182.00% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $90 | $5.36 | +1,579.10% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $14.33 | +1,644.59% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.21 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $65.67 | -11.68% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $18.55 | -35.31% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $6.50 | +469.23% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $89.65 | -38.65% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $3.27 | +756.27% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $27.73 | +94.73% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.82 | +5,362.49% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $20.28 | +33.14% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $458.12 | -70.10% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $7.92 | +506.06% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.89 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.06 | +2,730.19% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $77.26 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.48 | - | 2 | Jul 21, 2017 |
Novavax
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $6.91
Upside: -13.17%
ORIC Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $11.00
Upside: +81.82%
Olema Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $29 → $32
Current: $27.21
Upside: +17.60%
Enanta Pharmaceuticals
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $14.60
Upside: +16.44%
Syndax Pharmaceuticals
Nov 12, 2025
Maintains: Overweight
Price Target: $40 → $33
Current: $20.32
Upside: +62.40%
RAPT Therapeutics
Nov 12, 2025
Maintains: Overweight
Price Target: $55 → $57
Current: $34.40
Upside: +65.72%
Vera Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $44.90
Upside: +15.81%
Day One Biopharmaceuticals
Nov 7, 2025
Maintains: Overweight
Price Target: $26 → $27
Current: $7.92
Upside: +240.91%
BridgeBio Pharma
Nov 7, 2025
Maintains: Overweight
Price Target: $76 → $77
Current: $73.64
Upside: +4.56%
Amicus Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $9.90
Upside: +91.92%
Nov 5, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $5.77
Upside: +90.64%
Nov 5, 2025
Maintains: Overweight
Price Target: $40 → $36
Current: $23.63
Upside: +52.35%
Nov 3, 2025
Maintains: Overweight
Price Target: $171 → $179
Current: $155.51
Upside: +15.11%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $24.34
Upside: -1.40%
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $35.87
Upside: +120.24%
Oct 21, 2025
Maintains: Overweight
Price Target: $30 → $44
Current: $38.77
Upside: +13.49%
Oct 20, 2025
Upgrades: Neutral
Price Target: $11
Current: $10.61
Upside: +3.68%
Oct 10, 2025
Initiates: Overweight
Price Target: $200
Current: $220.36
Upside: -9.24%
Sep 29, 2025
Maintains: Overweight
Price Target: $27 → $37
Current: $41.71
Upside: -11.29%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.25
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $22.26
Upside: +7.82%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $44.41
Upside: +80.14%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $36.38
Upside: +221.61%
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $19.50
Upside: +161.54%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $35.00
Upside: +25.71%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $41.67
Upside: -4.01%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $109.60
Upside: +14.05%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.34
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.66
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $3.95
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.61
Upside: +182.00%
Aug 16, 2023
Maintains: Neutral
Price Target: $80 → $90
Current: $5.36
Upside: +1,579.10%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $14.33
Upside: +1,644.59%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $9.21
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $65.67
Upside: -11.68%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $18.55
Upside: -35.31%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $6.50
Upside: +469.23%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $89.65
Upside: -38.65%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $3.27
Upside: +756.27%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $27.73
Upside: +94.73%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.82
Upside: +5,362.49%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $20.28
Upside: +33.14%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $458.12
Upside: -70.10%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $7.92
Upside: +506.06%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $10.89
Upside: -
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.06
Upside: +2,730.19%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $77.26
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.48
Upside: -